




PHARMACEUTICAL 2018

NeuroBo Pharmaceuticals Inc.
Rank 296 of 342





PHARMACEUTICAL 2018

NeuroBo Pharmaceuticals Inc.
Rank 296 of 342

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 19% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 202% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	19,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,390
Liabilities, Non-Current	3.0
Other Assets	8.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,683
Other Net Income	-291
Other Revenues	0
Property and Equipment	0
Research and Development	22,686
Selling, General and Administrative Expense	10,438

Output Variable	Value in 1000 USD
Assets	19,017
Liabilities	15,076
Expenses	33,124
Revenues	0
Stockholders Equity	3,941
Net Income	-33,415
Comprehensive Net Income	-33,415
Economic Capital Ratio	-156%